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Abstract
Genetic deficiency in the expression of interleukin-10 (IL-10) is associated with the onset and
progression of experimental inflammatory bowel disease (IBD). The clinical significance of IL-10
expression is supported by studies showing that immune-augmentation of IL-10 prevents
inflammation and mucosal damage in animal models of colitis and in human colitis. Interleukin-10
(IL-10), an endogenous anti-inflammatory and immunomodulating cytokine, has been shown to
prevent some inflammation and injury in animal and clinical studies, but the efficacy of IL-10
treatment remains unsatisfactory. We found that intra-peritoneal administration of adenoviral IL-
10 to mice significantly reversed colitis induced by administration of 3% DSS (dextran sulfate), a
common model of colitis. Adenoviral IL-10 (Ad-IL10) transfected mice developed high levels of IL-
10 (394 +/- 136 pg/ml) within the peritoneal cavity where the adenovirus was expressed.
Importantly, when given on day 4 (after the induction of colitis w/DSS), Ad-IL10 significantly
reduced disease activity and weight loss and completely prevented histopathologic injury to the
colon at day 10. Mechanistically, compared to Ad-null and DSS treated mice, Ad-IL10 and DSS-
treated mice were able to suppress the expression of MAdCAM-1, an endothelial adhesion
molecule associated with IBD. Our results suggest that Ad-IL10 (adenoviral IL-10) gene therapy of
the intestine or peritoneum may be useful in the clinical treatment of IBD, since we demonstrated
that this vector can reverse the course of an existing gut inflammation and markers of inflammation.
I. Introduction
Endothelial cell adhesion molecules ('ECAMs') play
essential roles in the development of chronic inflamma-
tion by recruiting leukocytes, especially lymphocytes, to
tissues. ECAMs support several forms of leukocyte adhe-
sion including rolling, firm adhesion and extravasation
[1]. Infiltration of tissues by leukocytes is a common hall-
mark of many chronic inflammatory states that include
the inflammatory bowel diseases (IBD), ulcerative colitis
(UC), and Crohn's disease (CD). In the setting of IBD, the
expression of ECAMs like ICAM-1, VCAM-1, and MAd-
CAM-1 is observed in experimental models of colitis, and
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and ulcerative colitis [2-6].
Among the adhesion molecules up-regulated in IBD,
MAdCAM-1, the mucosal cell adhesion molecule, is
thought to be preeminent in the development of chronic
gut inflammation. MAdCAM-1 is normally expressed in
the gut, and its expression is dramatically amplified dur-
ing inflammation [2,3]. The functional significance of
increased appearance of MAdCAM-1 in IBD is supported
by several reports which show that immunoneutralization
of either MAdCAM-1 or its ligand, the α4β7 integrin,
attenuate inflammation and mucosal damage in animal
models of colitis [7-9]. However, since monoclonal anti-
bodies directed against other ECAMs, particularly VCAM-
1, can as well reduce disease activity in colitis models, the
literature suggests that MAdCAM-1 is probably necessary,
but insufficient for the maximal penetrance of experimen-
tal and probably also clinical IBD [10-13].
Based on these findings, it is apparent that a better under-
standing of the mechanisms regulating ECAM expression,
especially that of MAdCAM-1, might help to devise
improved therapies for colitis.
It has been suggested that pathologic activation of the
mucosal immune system in response to antigens is a key
factor in the pathogenesis of IBD. Furthermore, changes in
leukocyte migration and cytokine production appear to
contribute to the perpetuation of IBD [14]. Based on
modern advances, recombinant anti-inflammatory
cytokines (i.e. IL-10) treatment is now being developed
for experimental colitis and human IBD. IL-10 produced
by macrophages and monocytes appears to limit chronic
inflammation [15-17], through several mechanisms
including inhibition of the release of several inflamma-
tory factors (IL-1, IL-6, IL-12, TNF-α, GM-CSF, GCSF),
suppression of cell adhesive determinants (MHC class II
molecule, β7), and by blocking ICAM-1 induction [18-
24]. Conversely, IL-10 gene-knockout mice develop a
chronic colitis that is extremely similar to IBD [25]. IL-10
treatment can reduce inflammation in several models of
colitis and human IBD [26-30,18,31-34]. However, the
clinical efficacy of systemically administered IL-10 for
patients with mild to moderately active Crohn's disease
has not been as effective as hoped [31-34]. Furthermore
the efficacy of IL-10 administration in mouse colitis mod-
els is variable and model-specific [35].
We have previously described that exogenous IL-10 in
vitro can block the expression of MAdCAM-1 in response
to TNF-α, and attenuates lymphocyte adhesion to lym-
phatic node derived endothelium under cytokine stimu-
lating conditions via NF-kB inhibition [36]. The purpose
of the current study was to show that induction of
endothelial expression of IL-10 through an IL-10 expres-
sion vector attenuates MAdCAM-1 expression in response
to TNF-α and optimistically suggests the possibility of tar-
geted Th2-cytokine gene therapy in IBD.
II. Results
A. Measurement of human IL-10 concentration in lavage 
fluids from the transfected peritoneum
To screen for the efficacy of adenovirus mediated produc-
tion of IL-10 in transfected mice, we measured the IL-10
concentration in the lavaged peritoneum in untreated, in
adeno-'null' treated mice and in adeno-IL-10 transfected
mice. There was no detectable human IL-10 signal in the
non-transfected lavage fluid (control), nor was any mouse
IL-10 detected (data not shown). However, the lavage
fluid from the adenoviral IL-10 transfected mice showed a
large and signficant increase in the IL-10 concentration
(395 ± 136 pg/ml at 48 h after IL-10 gene transfection
(Figure 1). Importantly, IL-10 was not detected in serum
samples from these mice.
B. Reduced disease activity in adeno IL-10 gene 
transfected mice
A combinatorial index of disease, or disease acticvity
index (DAI), defined as stool blood, stool form, and
weight loss [37] was used to analyze the therapeutic ben-
efit of adenoviral gene delivery. We found that compared
to adeno-null or untreated mice, adenoviral IL-10 gene
transfection after induction of clinical disease reversed the
course of the disease induced by DSS (Figure 2).
IL-10 concentration in lavage fluids from the transfected per-itoneumFigure 1
IL-10 concentration in lavage fluids from the trans-
fected peritoneum. ELISA measurement of IL-10 in perito-
neal lavage fluids from control shows a very high level of 
expression of IL-10 at approximately 400 pg/ml. No IL-10 
was detected in lavage fluids of control or adeno-null mice (n 
= 5).Page 2 of 10
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mice during colitis
The anti-inflammatory effect of adenoviral IL-10 gene
transfer to mice was analyzed in experimental colitis
induced by feeding of oral 3% dextran sulfate (DSS,
MW~40–50 kD) over the course of 10 days, and body
weight recorded daily. Feeding behaviour was not altered
(measured by the weight of consumed food pellets, data
not shown). Body weight change in response to DSS was
significantly different from adeno-null mice at days 8, 9
and 10 but not different from adeno IL-10 treated mice
(Figure 3) consistent with a rescue from progressive
weight seen in untreated mice.
D. Colon shortening in DSS colitis and adenoviral IL-10
Animals fed DSS exhibited significant colon shortening
compared to controls, an effect which was eliminated by
adenoviral IL-10 gene transfer (Figure 4).
E. Adenoviral IL-10 significantly lowers histopathology 
score in DSS colitis
Perhaps the most remarkable finding in this study was the
histopathologic effect of adeno-IL-10 on gut histopathol-
ogy. Animals which had received adenoviral IL-10 vector
showed virtually no evidence of any inflammation (Figure
5c), although adeno-null animals showed significant
injury in response to DSS (Figure 5b) compared to con-
trols (Figure 5a). Interestingly, the level of inflammation
measured histopathologically in adenoviral IL-10 treated
mice given DSS was actually lower than that measured for
controls and may suggest that within the normal gut,
there is a persistent, low basal level of inflammation
which is normal, but that this mild inflammation can be
suppressed by additional supplementation with Th2
cytokines e.g. IL-10 (Figure 6).
F. Immunohistochemistry for MAdCAM-1
Staining of colon sections for the presence of MAdCAM-1
showed occasional staining in control treated sections. In
the null adenovirus treated mice receiving DSS, colon sec-
Disease activity in mice with experimental colitis given adenoviral IL-10 geneFigure 2
Disease activity in mice with experimental colitis given adenoviral IL-10 gene. Disease activity in mice in which 
experimental colitis was induced by feeding 3% DSS was significantly attenuated at days 7–10 when adenoviral administration of 
IL-10 was given on day 6. Disease activity in control mice continued at the same level as the adeno-null mice on DSS. Disease 
activity was slightly higher in adeno-null mice which was significant at day 8, suggesting that adenoviral infection produces some 
inflammation. This is important to note since Ad-IL-10 still promotes protection despite the tendency towards higher inflam-
mation.Page 3 of 10
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1 positive staining (indicated by white arrows in Figure
7b) over controls (Figure 7a), which is not observed in
adeno-IL-10/DSS treated samples (Figure 7c). Image anal-
ysis revealed a large and significant increase in vessel
staining from 40.33 +/- 2.79 (n = 38) in controls to 399 +/
- 58.5 (n = 49); this was significantly reduced by treatment
with adeno-IL-10 (79.4 +/- 22.8, n = 12) (p < 0.05, Dun-
netts test).
III. Discussion
Experimental colitis produced by DSS is thought to share
many important characteristics with forms of human
inflammatory bowel disease. We have previously shown
that a pre-emptive induction of interleukin-10 (using a
plasmid based expression vector) within endothelial cells
will significantly attenuate the expression of MAdCAM-1,
an important adhesive determinant which contributes to
the development of human IBD, in response to TNF-a
[38]. These effects may be due to enhanced endothelial
barrier function [39], or to effects on adhesion molecules
e.g. MAdCAM-1 and other endothelial cell adhesion mol-
ecules [4]. This is further supported by in vivo studies
where animals genetically deficient in IL-10 develop
spontaneous colitis with many of the characteristics of
human IBD and clinical studies where IL-10 has shown
some benefit in the treatment of human IBD [40].
Adeno-IL-10 blocks colon shortening induced by DSS colitisFigure 4
Adeno-IL-10 blocks colon shortening induced by DSS 
colitis. Adenoviral IL-10 adminstration significantly reduced 
the colon shortening produced by 3% DSS colitis (n = 5).
Body weight of mice in DSS colitisFigure 3
Body weight of mice in DSS colitis. Adeno-IL-10 mice did not lose any body weight over the course of DSS colitis, but 
adeno-null mice lost significantly more weight than adeno-IL-10 transfected mice (n = 5).Page 4 of 10
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to be effective at preventing the induction of experimental
colitis, it has of course proven more difficult to reduce an
existing level of inflammatory bowel disease, since the
disease process may be highly complex and difficult to
control by altering a single mediator. However, models
which can demonstrate effective attenuation of existing
disease may provide the most relevant and important
models of how human disease can be treated [41].
We showed that an adenoviral IL-10 expression vector is
capable of producing very high levels of IL-10 within the
peritoneal compartment, the bulk of which appears to
remain confined to the peritoneal cavity, since IL-10 is not
detected in plasma or serum samples following adenovi-
ral transfection. Expression of MAdCAM-1 has also been
reported in the brain, and in the heart; based on these
findings, it has now been suggested that MAdCAM-1
might play roles in chronic inflammation of these organs
as well [42,43].
In normal biology and especially during active inflamma-
tory bowel disease, MAdCAM-1 may be essential to the
lymphocyte homing to mucosa associated lymphoid tis-
Colon histology for adenoviral transfected mice given DSS colitisFigure 5
Colon histology for adenoviral transfected mice given DSS colitis. Figure 5A shows control colons with normal his-
topathology, 5B shows extensive regional leukocytic infiltration of the colon; see inset. This leukocyte infiltration is completely 
absent in adenoviral IL-10 treated mice which show normal or even improved morphology.Page 5 of 10
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expressed mainly within the gut microvasculature, and is
dramatically amplified during IBD, it has been suggested
that increased MAdCAM-1 expression contributes to the
etiology of IBD through its ability to direct homing of
lymphocytes to the gut. This notion is well supported by
several reports that show that antibodies directed against
either MAdCAM-1, or its lymphocyte ligand, the α4β7
integrin, will significantly attenuate several indices of gut
damage in experimental models of colitis [8,46]. Further-
more, clinical studies conducted by Feagan et. al (2005)
indicate that a humanized antibody against α4β7, an
important MAdCAM-1 ligand administered to patients
with active ulcerative colitis, effectively reduced the sever-
ity of the disease in comparison to those patients who
received the placebo [47].
Several studies have indicated that T helper (Th1)
immune responses have important roles in the develop-
ment of IBD [48-50]. Moreover, dysregulation of cytokine
networks is involved in Th1-dominant immune responses
in IBD. Among the Th1 cytokines, TNF-α is thought to be
perhaps the most important cytokine responsible for driv-
ing the onset and evolution of IBD. Because of this prime
role of TNF-α in IBD, anti-TNF-α antibody therapy has
been very successfully used in IBD to reduce both colonic
injury and expression of ECAMs in IBD [51].
IL-10, a cytokine produced by activated macrophages and
Th2-type T cells, has crucial inhibitory effects on the Th-1
type immune response, as well as on the antigen-present-
ing function of monocytes and macrophages [15,16]. IL-
10 appears to play an important role in preventing the
onset of IBD, since animals deficient in IL-10 develop col-
itis spontaneously, and low levels of IL-10 are positively
correlated with recurrences of Crohn's disease [25,52].
However, unlike TNF-α based therapies, administration
of recombinant IL-10 (rIL-10) shows poor efficacy. This
may reflect the fact that TNF-α therapies for IBD are aimed
at efficiently clearing TNF-α, while IL-10 therapies must
increase IL-10 and recombinant IL-10 is likely too rapidly
cleared from the circulation after in vivo administration to
produce a uniform protection [53]. On the other hand, IL-
10 gene transfer technology has been used with some suc-
cess in models of colitis, however its efficacy is variable.
One reason for this variability may be that the final serum
IL-10 concentration of gene-transfected mice is below the
threshold level needed for gut protection [53,54]. There-
fore targeting of the IL-10 gene to the inflamed colon or
its compartment should ideally exploit tissue (i.e. gut)
specific promoters to control selective organ gene transfer
technology, endothelial specific promoters and also organ
specific intra-arterial injection of vector to activate some
genes in specific locations [55].
Administration of IL-10 in vitro prevents TNF-α stimulated
expression of MAdCAM-1 and also blocks lymphocyte
adhesion on endothelial cells to the same level as dexam-
ethasone treatment, currently a key therapy in IBD [36].
While it has been previously shown that delivery of IL-10
to the endothelium in vitro is protective against TNF-α
[36], in vivo administration of IL-10 may be less effective
[33]. Therefore methods like endothelial gene transfec-
tion in vivo may effectively maintain adequate IL-10 con-
centrations at the endothelial surface to finally achieve
protection not obtained with intravenous IL-10 adminis-
tration.
The most important index of efficacy for gene mediated
recombinant IL-10 delivery in IBD is the effective inhibi-
tion of the lymphocyte-endothelium interaction medi-
ated by MAdCAM-1. In this experiment, IL-10 induction
in the endothelium efficiently blocked TNF-α induced
MAdCAM-1 expression and α4β7-dependent lymphocyte
adhesion on SVEC endothelial cells. Although we have
not used tissue specific promoters, their use might permit
even greater organ selective transgene delivery.
Our findings suggest that lymphatic or gut endothelial
transfection with Th2 cytokines like IL-10 may be an effec-
tive method to reduce important symptoms associated
with IBD.
IV. Experimental procedures
A. Adenoviral IL-10 gene transfer
Adenoviruses
The AdvIL-10 construct was a generous gift from Thomas
Ritter, Institute of Medical Immunology, Charite-Campus
Analysis of histopathology in adenoviral transfected DSS coli-tis modelFigure 6
Analysis of histopathology in adenoviral transfected 
DSS colitis model. Compared to control mice, adeno-null 
treated mice exhibited significantly worse histopathology; 
whereas adeno-IL-10 treated mice had completely normal 
histology.Page 6 of 10
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trol Ad-null construct, consisting of an E1a deleted Ad
with no CMV promoter and no transgene cassette, was
provided by Canji, Inc. (ZZNB; San Diego, CA). High titer
adenoviral stocks were propagated in 293 cells and puri-
fied by cesium chloride gradient centrifugation. Banded
virus was removed, desalted by dialysis in storage buffer
(1 M sucrose, 5 mM alpha-cyclodextrin (Sigma) in PBS),
and stored in small aliquots at -80°C. Repeated freeze/
thaw cycles of the Ad stocks were avoided. Viral stocks and
infected cells were handled only in a Class II laminar flow
hood and maintained in a CO2 incubator designated for
that purpose. The concentration of total viral particle
numbers (PN) was determined by measuring the absorb-
ance of the stocks at 260 nm. Infectious PNs were deter-
mined by measuring the concentration of viral hexon
protein-positive 293 cells after a 48-h infection period.
Multiplicity of infection (m.o.i.) was determined using an
Adeno-X Rapid Titer Kit (Clonetics).
B. Evaluation of Clinical Colitis
The mice were C57B6 mice, males which were obtained at
6–8 weeks of age, and used at 8–10 weeks of age, with an
average weight of 23 g at the beginning of the experi-
ments. Mice were fed either water or 3% DSS as previously
described, [56]. In all animals, weight, stool blood, pres-
ence of gross blood and stool consistency were deter-
mined daily as previously described [37]. Disease activity
Adenoviral IL-10 reduces MAdCAM-1 expression in experimental colitisFigure 7
Adenoviral IL-10 reduces MAdCAM-1 expression in experimental colitis. Figure 7A (control) shows only sporadic 
and weak staining for MAdCAM-1. Figure 7B shows intense MAdCAM-1 staining in adeno-null + DSS-treated colon sections, 
unlike Adeno-IL10 + DSS-treated sections (Figure 7C) which lack strong MAdCAM staining, and much more closely resemble 
controls.Page 7 of 10
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weight loss b) stool consistency and c) bleeding (divided
by 3). Each score was determined as follows, change in
weight (0:<1%, 1: 1–5%, 2: 5–10%, 4:>15%), stool blood
(0: negative, 2: positive) or gross bleeding (4), and stool
consistency (0: normal, 2: loose stools, 4: diarrhea) as pre-
viously described [57]. Bodyweight loss was calculated as
the percent difference between the original bodyweight
and the actual bodyweight on any particular day. Typi-
cally in DSS colitis animals will lose 10–15% body weight
over the course of 10 days. The appearance of diarrhea is
defined as mucus/fecal material adherent to anal fur. The
presence or absence of diarrhea was scored as either 1 or
0, respectively, and the cumulative score for diarrhea was
calculated by adding the score for each day and dividing
by the number of days of exposure. Rectal bleeding was
defined as diarrhea containing visible blood/mucus or
gross rectal bleeding and scored as described for diarrhea.
Occult blood was detected using the 'Coloscreen' (Helena
Laboratories, Beaumont, TX). At the end of these studies
mice were anesthetized with high dose ketamine/xylazine
(200 ul/animal) with carbon dioxide asphyxia prior to
collection of tissues.
C. MadCAM-1 Immunohistochemistry
3 mm sections of tissue were frozen in OCT embedding
compound and 15 um frozen sections collected onto 1%
gelatin coated slides. Sections were incubated in 1:100
diluted primary anti-mouse MAdCAM-1 antibody in
0.1% milk powder in PBS for 12 h, washed 3× in this
buffer, incubated in 1:1000 goat anti-rat Cy3 labeled anti-
body for 1 h, washed 3× and then mounted in Vectashield
(Vectorlabs, Burlingame, CA). Images were analyzed for
vessel staining (area) using the Image-J software package
(NIH, Bethesda, MD, http://rsb.info.nih.gov/ij/).
E. Morphological analysis
Mice were killed on day 10 of the experiment, organs were
removed and fixed in 3.7% phosphate buffered formalde-
hyde. Sections of the distal colons were cut into 1 cm
pieces and then embedded in epon/aryldite (Ted Pella).
General histological assessment and scoring was carried
out on sections stained using haematoxylin and eosin.
F. Histological scoring
Histological scoring was performed on operator blinded
sections using the standardized histological point system
described by Cooper et al., which is used routinely for his-
tological scoring of IBD severity [57]. A score of 0 reflects
normal epithelium, without blunting, normal crypt
appearance, low monocyte infiltration, and low or absent
neutrophil infiltration. Three serial sections of five to six
different sites of the colon (accounting for up to 18 sec-
tions per mouse) were examined at 200 × magnification;
the most affected part was scored, ulceration being con-
sidered the worst lesion. A score of 1 indicates loss of sin-
gle epithelial cells, mild blunting of the epithelium, single
inflammatory cell infiltration of crypts, slight monocyte
and neutrophil infiltrate; a score of 2 signifies loss of mul-
tiple epithelial cells (in patches), obvious flattening of the
epithelia, cryptitis, and a moderate increase in monocytes
and neutrophils; a score of 3 indicates frank epithelial
ulceration with crypt abscesses and a marked increase in
monocyte/neutrophils.
G. Statistical analysis
All values are expressed as mean ± SD. Data were analyzed
using multiple comparisons. Probability (P) values of
<0.05 were considered significant.
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